VEGF-165 — Vendor Pricing & Purity Guide
Research Overview
VEGF-165 (Vascular Endothelial Growth Factor 165) is the most biologically active isoform of VEGF-A, the master regulator of angiogenesis (new blood vessel formation). It is a homodimeric glycoprotein that binds VEGFR-1 and VEGFR-2 receptors on endothelial cells, triggering proliferation, migration, and new vessel formation.
VEGF-165 is used primarily in wound healing and tissue engineering research. Conversely, VEGF inhibitors (anti-VEGF drugs like bevacizumab) are major cancer therapeutics that starve tumors by blocking angiogenesis.
Key Research Findings
- •Master regulator of angiogenesis — the primary signal for new blood vessel formation
- •Most active VEGF-A isoform, binding both VEGFR-1 and VEGFR-2
- •Critical for wound healing, tissue engineering, and ischemic tissue recovery research
- •Anti-VEGF drugs (the opposite approach) are blockbuster cancer therapeutics
Research Dosage Protocols
VEGF-165 is a recombinant protein requiring careful handling. Supplied as lyophilized powder, reconstituted with sterile buffer. Used at ng/mL concentrations in cell culture and µg-level doses in animal models.
For research reference only. Not medical advice. Not for human consumption.
Price Comparison (0 products from 0 vendors)
No vendor pricing data yet for VEGF-165.
Frequently Asked Questions
What is VEGF-165?
VEGF-165 is the most active form of VEGF, the master regulator of new blood vessel formation. It is used in wound healing and tissue engineering research.